###### Key messages

What is already known about this subject?
=========================================

-   Patients with lupus have been reported to have restricted gut microbiome diversity and general patterns of dysbiosis but few patients with active disease have been previously characterised.

What does this study add?
=========================

-   Patients with lupus were found to have characteristic patterns of gut microbiome dysbiosis that directly paralleled disease activity.

-   Patients with systemic lupus erythematosus commonly displayed signs of impaired gut barriers that may result in immune exposure to gut commensal bacteria.

-   Intestinal expansions of *Ruminococcus gnavus* (*RG*) were directly proportional to overall disease activity and most pronounced in those with lupus nephritis. Lupus faecal samples displayed increases in sIgA-coated *RG* bacteria. In three independent cohorts, patients with lupus nephritis displayed elevated serum IgG predominantly to *RG* strain-restricted cell wall lipoglycan antigens.

How might this impact on clinical practice or future developments?
==================================================================

-   Identification of *R. gnavus* as a candidate pathobiont opens new areas of investigation of the mechanistic basis by which these outgrowths may affect the overall pathogenesis of lupus and the immune complex-mediated pathogenesis of lupus nephritis.

-   These findings may lead to the development of bioassay(s) with prognostic value for the risk of lupus nephritis.

Introduction {#s1}
============

Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease with hallmarks of B-cell abnormalities, circulating autoantibodies to nuclear antigens and immune-complex formation.[@R1] The heterogeneity of disease presentation and organ involvement in different individuals, and the variability of disease activity from remission to exacerbations and progression, all contribute to clinical challenges for diagnosis and effective management. Indeed, such heterogeneity suggests that SLE may not represent a single disease but rather several.

Serum autoantibodies to native DNA are a specific diagnostic criterion for SLE,[@R2] and a prognostic factor for the development of lupus nephritis (LN) that affects 30%--60% of patients.[@R3] However, the earliest reports of antibody responses to nucleic acids/nucleoproteins were documented in association with clinically apparent bacterial infections.[@R4] Yet two decades later autoantibodies to nuclear antigens were recognised to be a common feature of SLE.[@R7] Indeed, some DNA-reactive autoantibodies are directly nephritogenic in animal models.[@R10] Conversely, only \~20% of the IgG eluted from lupus kidneys is DNA-reactive,[@R11] suggesting that other antibody reactivities may also contribute to the pathogenesis of LN.[@R12]

While a transmissible agent has long been suspected in lupus pathogenesis, only recently has suitable technology become available that enable in-depth consideration of the potential roles of the immense dynamic communities of commensal microorganisms that coevolved with our species. The largest microbiome community resides within our gut, where these microbes play essential roles, including for the early priming of our immune systems[@R13] and subsequent immune regulation.[@R14] Mounting evidence has implicated imbalances within these gut microbial communities, also termed dysbioses, in the autoimmune pathogenesis of several diseases: inflammatory bowel disease (IBD), type 1 diabetes, multiple sclerosis and rheumatoid arthritis.[@R15] Yet, there have only been a few reports on the human lupus microbiome, in small cohorts that have included only a few active patients.[@R16]

In the present study, we investigated the gut microbial communities in a cross-sectional cohort of 61 female patients with lupus heterogeneous for ethnicity/race, disease activity and organ involvement and immune profiles. Key findings were then evaluated in two independent lupus cohorts.

Methods {#s2}
=======

Ethics statement {#s2-1}
----------------

The study was conducted according to the Declaration of Helsinki. Before study inclusion, written informed consent, approved by the NYU IRB, was obtained from all subjects for research use and publication of their data.

### Study design {#s2-1-1}

Patients were consecutively recruited from the NYU Langone Medical Center and Bellevue Hospital. All patients fulfilled the American College of Rheumatology Criteria for the diagnosis of SLE.[@R2] Further details on trial-specific inclusion and exclusion criteria, clinical evaluations, sampling and 16S rRNA amplicon analyses are described in the [supplementary data](#SP1){ref-type="supplementary-material"}. Sections on immunoassays, as well as culture of bacterial strains and purification of *R. gnavus* lipoglycans (LGs) are also provided (see [supplementary materials](#SP1){ref-type="supplementary-material"}).
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Results {#s3}
=======

Patients with lupus have distinctive patterns of dysbiosis that parallel disease activity {#s3-1}
-----------------------------------------------------------------------------------------

In the discovery phase of our studies, we analysed the faecal microbiota of 61 female patients with lupus in a cross-sectional urban cohort and 17 female healthy controls ([online supplementary table 1](#SP2){ref-type="supplementary-material"}). Our patients displayed great heterogeneity in their organ involvement, and in disease activity from clinical remission to highly active, that was scored using the composite SLE disease activity index (SLEDAI).[@R19]
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To define the richness of alpha diversity in gut communities, Chao1 estimates of the total number of operational taxonomic units[@R20] demonstrated that the overall biodiversity of the intestinal microbiota in patients with lupus was significantly restricted compared with unaffected female adult controls (Mann-Whitney, p=0.038) ([figure 1A](#F1){ref-type="fig"}). Among patients with lupus, there was a numerical trend towards an inverse correlation of Chao1 estimates of alpha diversity with SLEDAI score (Mann-Whitney, p=0.08) (data not shown). Moreover, after empirically considering all possible cut-off values to dichotomise patients based on SLEDAI score, those with high disease activity (defined as SLEDAI ≥8) displayed significantly restricted microbiota diversity compared with controls (Mann-Whitney, p=0.003) ([figure 1A](#F1){ref-type="fig"}).

![Patients with SLE have altered faecal communities of commensal taxa, elevated faecal immunoglobulin levels and biomarker evidence of altered gut barrier function. (A) Chao1 estimates of alpha diversity represent the total expected number of OTUs that represent quasi-species identified from 16S rRNA amplicon sequencing surveys, with larger values representing higher diversity. Patients with SLE (n=61) have less diverse faecal microbiota than healthy controls (n=17), indicating that SLE commonly have intestinal dysbioses. At far right, the distribution of Chao1 values in patients with SLE with high activity (ie, SLEDAI≥8) was significantly contracted compared with healthy adult controls (HC), with a trend towards more limited diversity in SLE with high disease activity when compared with SLE with low disease activity. We used a cut-point that was associated with greatest statistically significant differences. The SLE low disease activity group had a range of 0--7 SLEDAI scores (n=47), and SLE high disease activity group had scores of 8--18 (n=14). p values were based on the Mann-Whitney test. (B) PcoA showed that the beta diversity within bacterial communities in the faecal microbiomes in healthy controls was less different than the communities from patients with SLE low disease activity (PERMANOVA, p=0.02). Furthermore, healthy subjects were more like one another than were patients with SLE. (C) Results indicate average within group beta diversity differences in the three different groups, with comparisons for Control-SLEDAI^hi^-SLEDAI^low^, p=0.002. The binary comparison, control vs SLE had p=0.02. Both comparisons were done using PERMANOVA test. Examinations of faecal extract demonstrated patients with SLE commonly display: (D) elevated faecal sIgA levels, (E) elevated faecal IgM levels, (F) elevated faecal IgG levels, and (G) elevated faecal calprotectin. Patients with SLE also displayed: (H) elevated serum sCD14 levels and (I) elevated serum α1-acid glycoprotein levels, as measured by commercial assay. Results are for the NYU cohort of adult female patients with SLE, were compared to adult female controls without inflammatory or autoimmune disease (CTL). (D--F) and (H--I) using unpaired two-tailed *t* test with Welch's correction, (G) used Mann-Whitney test. Significance for p\<0.05. OTUs, operational taxonomic units; PCoA, principal coordinates analysis; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.](annrheumdis-2018-214856f01){#F1}

The human gut microbiome is dominated by four bacterial phyla---*Firmicutes, Bacteroidetes, Actinobacteria* and *Proteobacteria---*with thousands of different species and countless strains in complex dynamic relationships within individual gut communities.[@R21] To visualise community variation, we performed principal coordinates analyses that confirmed that taxonomic distributions within patients with SLE were significantly different than in controls (PERMANOVA, p=0.02) ([figure 1B](#F1){ref-type="fig"}). When the patients with SLE were stratified by high or low disease activity, the beta diversity differences were even more pronounced (PERMANOVA, p=0.002, data not shown). Furthermore, the variability in beta diversity of healthy subjects was lower than in patients with lupus ([figure 1B, C](#F1){ref-type="fig"}). The within group variability between communities in patients with lupus with low disease activity was also lower than that in patients with high disease activity ([figure 1C](#F1){ref-type="fig"}). However, the severity of the detected disease-associated dysbiosis did not correlate with disease duration ([online supplementary figure 1A](#SP3){ref-type="supplementary-material"}).
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With 16S rRNA amplicon sequence analysis, the taxa in each community with the most highly abundant (\>1%) representation at all phylogenetic levels were identified by univariate Kruskal Wallis ANOVA analysis ([Table 1](#T1){ref-type="table"} and online [supplementary table 2](#SP4){ref-type="supplementary-material"}). At the species level, patients with SLE displayed a mean 5-fold overabundance of an anaerobic Gram-positive taxon in the Firmicutes phylum and *Lachnospiraceae* family, identified as *Ruminococcus gnavus* [@R23] *(RG*) (range 0.00%--10.79%, mean±SD 1.35%±2.01%) compared with controls (0.00%--1.27%, 0.25%±0.39%, Mann-Whitney, p=0.01). Strikingly, *RG* relative abundance correlated with lupus disease activity, as even patients with SLE with low disease activity had a mean 4-fold *RG* overrepresentation, while those with high disease activity had \>8 fold greater *RG* abundance (Mann-Whitney, p=0.01) ([table 1](#T1){ref-type="table"}, complete data in [online supplementary table 2](#SP4){ref-type="supplementary-material"}). Compared with those without a history of renal disease, patients with a history of renal involvement displayed an even greater abundance of a RG specific amplicon sequence variant (ASV) (Mann-Whitney, p=0.04), as well as several other ASVs that included two assigned to the Veillonella genus ([online supplementary table 3](#SP5){ref-type="supplementary-material"}). In an individual community these *Veillonella* species were highly correlated with each other (CLR-transformed, r=0.89, p\<10^--16^) although less strongly with *RG* (39% *V*. *parvula*, 43% *V*. *dispar*, p\<0.005). Hence, the microbiota in patients with lupus commonly displayed concurrent expansions of both *RG* and *Veillonella* species.
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###### 

Shifts in taxonomic abundance in SLE by disease activity

  Taxonomic level   Taxonomy                  Healthy (%)   SLEDAI^low^ (%)   SLEDAI^high^(%)   P value
  ----------------- ------------------------- ------------- ----------------- ----------------- ---------
  Class             *Erysipelotrichi*         1.37          1.44              5.92              0.086
  Order             *Erysipelotrichales*      1.37          1.44              5.92              0.086
  Family            *Erysipelotrichaceae*     1.37          1.44              5.92              0.086
  Family            *Veillonellaceae*         1.58          3.41              12.27             0.008
  Family            *Ruminococcaceae*         25.66         11.68             15.11             0.045
  Genus             Blautia                   2.23          4.10              3.59              0.077
  Genus             Ruminococcus              0.53          1.76              3.15              0.007
  Species           *Ruminococcus gnavus*     0.25          1.19              2.11              0.013
  Species           *Bacteroides uniformis*   2.11          0.87              0.34              0.014
  Species           *Bacteroides fragilis*    1.17          2.41              2.20              0.081

Results from univariate Kruskal-Wallis ANOVA analysis of 16S rRNA abundance for all taxa across all subjects for p\<0.10 and not FDR corrected. The same bacterial set is identified as *Erysipelotrichi, Erysipelotrichales* and *Erysipelotrichaceae*. SLEDAI^low^ patients have SLEDAI scores of less than 8. For the complete analysis, see [online supplementary table 2](#SP4){ref-type="supplementary-material"}.

ANOVA, analysis of variance; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.

As an alternative approach, DADA2[@R24] was used to assign ASVs (ie, quasi-species): patients with a history of renal disease displayed increased representation of ASV31 (Mann-Whitney, p\<0.05) ([online supplementary tables 2-4](#SP4 SP5 SP6){ref-type="supplementary-material"}). In fact, this ASV identifies *RG* and has the predictive effect size of AUC=0.65 for renal involvement (see Ref. [@R25] for description of predictive effect size analysis protocol), although this study was not adequately powered for multiple comparison correction. Nonetheless, these findings collectively indicate that patients with LN commonly have intestinal expansions of the *RG* species.

The lupus microbiome is associated with altered dynamic relationships between species {#s3-2}
-------------------------------------------------------------------------------------

Within microbiome communities, we also looked for evidence of coordinated shifts in the representation of species within individual lupus communities, and outgrowths of *RG* were found to be commonly associated with reciprocal reductions of the *Bacteroides uniformis* species (r=−0.43, Pearson correlation for CLR-transformed abundances, p\<0.001). Indeed, lupus patients with the highest disease activity scores also had the lowest abundance of *B. uniformis* (Mann-Whitney, p=0.01) ([table 1](#T1){ref-type="table"}), suggesting that these species may be in dynamic reciprocal relationships. Notably, as *B. uniformis* conveys anti-inflammatory properties that can ameliorate metabolic abnormalities in diabetes-prone mice,[@R26] a paucity in active lupus patients could also be relevant to understanding the drivers of autoimmune pathogenesis.

Evidence of *in vivo* gut recognition of *RG* and altered gut barrier function {#s3-3}
------------------------------------------------------------------------------

To assess *in vivo* local recognition of specific gut taxa, we evaluated the representation of secretory IgA (sIgA)-coated faecal bacteria recovered from 15 unaffected controls and 23 patients with SLE ([online supplementary figure 1B](#SP3){ref-type="supplementary-material"}). Overall, *RG* bacteria were prominent among sIgA-coated subcommunities by 16S rRNA analysis, and lupus samples displayed a 2-fold greater abundance of *RG* among sIgA-coated faecal bacteria than healthy controls, However, in these limited surveys, the numerical differences did not attain significance (Wilcoxon rank sum, p=0.14, not significant) ([online supplementary figure 1C](#SP3){ref-type="supplementary-material"}).

In healthy individuals, an intact intestinal barrier prevents leakage of luminal contents out of, and also systemic IgG from entering into, the gut lumen. In these faecal samples, patients with lupus had 2.6-fold overall sIgA elevations vs controls (Welch test, p=0.002) ([figure 1D](#F1){ref-type="fig"}). Furthermore, the elevations of faecal IgM in patients with lupus, as well as the increases in faecal IgG, provide additional circumstantial evidence of an impairment of the epithelial barrier in these patients ([figure 1E, F](#F1){ref-type="fig"}).

To further search for evidence of impaired gut barriers, we measured faecal levels of calprotectin, an accepted biomarker for intestinal barrier defect.[@R27] In these pilot studies, we foud that 12/61 patients with lupus exceeded the level in any of the tested control subjects (Mann-Whitney, p=0.03) ([figure 1G](#F1){ref-type="fig"}). Furthermore, patients with lupus also displayed raised serum soluble CD14 (Welch test, p=0.0002) and raised α1-acid glycoprotein levels (Welch test, p\<0.0001) ([figure 1H, I](#F1){ref-type="fig"}), which in other conditions have been attributed to gut bacterial translocation.[@R28] Taken together, these findings suggest that patients with lupus may at times experience impaired gut barrier function, which potentially may enable commensals, or their components, to escape the intestinal lumen.

Lupus serum IgG antibodies react with a *RG2* strain-associated non-protein antigen {#s3-4}
-----------------------------------------------------------------------------------

To investigate for a special immune relationship in patients with SLE with their candidate pathobionts, we electrophoretically separated the components in extracts of eight monocultured *RG* strains ([online supplementary table 5](#SP7){ref-type="supplementary-material"}) after treatment with lysozyme and endonuclease. Immunoblots revealed that many patients with lupus and healthy adult controls had IgG reactivity with antigenic bands, common to a range of *RG* strains ([figure 2A--D](#F2){ref-type="fig"}), and these were protease-sensitive ([figure 2E](#F2){ref-type="fig"}). In contrast, lupus serum antibodies were not generally reactive with commensal strains *P. copri* or *B. thetaiotaomicron* ([figure 2A--C](#F2){ref-type="fig"}). Notably, serum IgG antibodies of lupus patients with SLEDAI activity scores of ≥8 were often highly reactive with specific conserved protease-resistant bands in the extract of the *R. gnavus* strain CC55_001C, which is here termed *RG*2 ([online supplementary table 5](#SP7){ref-type="supplementary-material"}). These conserved bands in the *RG2* strain migrated with \~20--30 kDa protein markers, but such bands were not detected in the seven other *RG* strains tested ([figure 2E](#F2){ref-type="fig"}).
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![Patients with LN have serum IgG that recognise *RG2* strain-restricted non-protein antigen(s) and that levels correlate with scores forlupus disease activity. Immunoblot results for IgG from (A) patient with LN (S-134), (B) patients with LN (S-047), (C) patient with non-active lupus (S-096) and (D*)* healthy control (CTL23). Bacterial extracts were prepared with nuclease and lysozyme treatment; lanes 1--8 represent *R. gnavus RG1-RG8* strains (see [online supplementary table 4](#SP6){ref-type="supplementary-material"}), and lanes 9 and 10 contain extracts from gut commensal species, *Bacteroides thetaiotaomicron* and *Prevotella copri*. After electrophoretic transfer, replicate membranes were incubated with different sera at 1:100 dilution, with detection for human IgG deposition. Only patients with highly active lupus had serum IgG that recognised the oligomeric antigenic band in *RG2* (red arrow) that was not detected in other *RG* strains. (E) Immunoblot of human gut isolated strains of *R. gnavus*, *RG1-RG8*. For each strain, molecular species were electrophoretically separated side-by-side, after nuclease and lysozyme treatment (left lane) and after additional thorough proteinase K treatment (right lane). Reactivity for serum IgG from patient S-134 with active LN is shown, with the serum tested at 1:100. Inset shows magnified view of non-protein oligomeric bands in *RG2* extract, which are also seen in panels A and B. (F) In patients with SLE, *RG* faecal abundance by 16S rRNA analysis correlates with the levels of serum IgG anti-*RG2* antibody. (G) Levels of serum IgG anti-*RG2* in individual patients with lupus in the NYU cohort were compared with unaffected adults (see Methods section). Patients with SLE with high disease activity (SLEDAI ≥8) had higher levels of anti-*RG2* IgG antibodies than healthy controls and than SLE with low disease activity. (H) Levels of serum IgG antinative DNA directly correlate with IgG anti-*RG2* antibodies. Results from multiplex assay using extracts treated with lysozyme and a broad endonuclease, which was separately coupled to a set of paramagnetic beads (Luminex) in parallel with other antigens. (I) Levels of IgG anti-*RG2* directly correlate with IgG to an extract of human glomeruli. Results from multiplex assay. (J) Levels of serum C3 inversely correlated with levels of serum lupus IgG anti-*RG2* antibodies in patients with SLE. (K) Levels of serum C4 inversely correlated with levels of serum lupus IgG anti-*RG2* antibodies in patients with SLE. (L) IgG anti-*RG2* levels strongly correlate with serum IL-6 levels. (M) Levels of IgG anti-dsDNA, determined by commercial ELISA (INOVA), have only a modest correlation with serum IL-6 levels. (N) IgG anti-*RG2* levels correlate with IFNα2 levels, determined by commercial bead-based assay (Luminex). (O) Levels of IgG anti-dsDNA antibodies do not correlate with serum IFNα2 levels. IgG anti-DNA and *RG2* levels were measured by in-house custom bead-based assays. C3 and C4 were measured with commercial ELISA, while cytokines were measured by commercial bead-based assays. Significance was based on Mann-Whitney test or Spearman correlations. LN, lupus nephritis; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.](annrheumdis-2018-214856f02){#F2}
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High antibody responses to the candidate *RG* pathobiont correlate with high disease activity {#s3-5}
---------------------------------------------------------------------------------------------

Given the common overabundance of *RG* in patients with active SLE, we investigated for special host-pathobiont relationships within the systemic immune systems of affected individuals. Serum IgA-anti-*RG2* antibody responses were significantly higher in patients with SLE than controls, even after normalisation for total IgA levels (Welch test, p=0.01) ([online supplementary figure 1D, E](#SP3){ref-type="supplementary-material"}). Strikingly, serum IgG anti-*RG2* responses were also increased in patients with SLE, and in matched lupus samples we found a significant direct correlation between the relative faecal abundance of the candidate *RG* pathobiont with the levels of serum IgG anti-*RG2* antibodies (Spearman, p=0.002) ([figure 2F](#F2){ref-type="fig"}) but not with the VPI C7-9 strain, here termed *RG1* ([online supplementary table 5](#SP7){ref-type="supplementary-material"} and data not shown), however such a relationship was also not found in studies of control subjects (not shown).

Based on a cut-off defined by values from unaffected control subjects (see Methods section), significant elevations of serum IgG anti-*RG2* antibodies were detected in 22.9% of patients with SLE in the NYU cross-sectional cohort ([figure 2G](#F2){ref-type="fig"}). Furthermore, serum levels of IgG anti-*RG2* strain antibodies directly correlated with SLEDAI disease score (Spearman, p=0.04) but not with the serum IgG antibodies to the *RG1* strain ([online supplementary figure 1F](#SP3){ref-type="supplementary-material"}). When patients were dichotomised based on disease activity the statistical differences between these patient subsets were most pronounced, as patients with SLEDAI scores≥8 had significantly higher IgG antibody levels to *RG2* than patients who were quiescent or had only low disease activity (Mann-Whitney, p\<0.001) ([figure 2G](#F2){ref-type="fig"}), suggesting that the IgG anti-*RG2* antibody level could represent a surrogate disease activity marker.

Serum levels of IgG anti-*RG2* strain antibodies correlated with anti-native DNA autoantibodies (Spearman, p*\<*0.0001) ([figure 2H](#F2){ref-type="fig"}), which are commonly found in patients with LN.[@R2] IgG antibodies to *RG2* were also significantly positively correlated with IgG reactivity against human glomerular extract (Spearman, p\<0.0001) ([figure 2I](#F2){ref-type="fig"}), which is reported to identify the most nephritogenic anti-DNA antibodies.[@R31] In contrast, there was neither an association with other types of lupus-associated autoantibodies, including anti-Ro52, nor with total IgG levels ([online supplementary figure 1G, H](#SP3){ref-type="supplementary-material"}). Relevant to clinical disease state, levels of IgG anti-*RG2* antibodies also inversely correlated with C3 (Spearman, p\<0.01) and C4 levels (Spearman, p\<0.007) ([figure 2J, K](#F2){ref-type="fig"}), biomarkers for *in vivo* activation of the complement cascade implicated in active immune-complex-mediated pathogenesis in LN.[@R30] Indeed, serum IL-6 displayed a strong direct correlation with IgG anti-*RG2* levels (Spearman, p=0.003) ([figure 2L](#F2){ref-type="fig"}), while the relationship with anti-dsDNA was more modest (Spearman, p*=*0.02) ([figure 2M](#F2){ref-type="fig"}). Furthermore, serum α2-interferon (IFN) also correlated with IgG anti-*RG2* levels (Spearman, p=0.015), while there was no correlation with anti-dsDNA in the same samples ([figure 2N, O](#F2){ref-type="fig"}). These findings provide circumstantial evidence of a connection between host immunity to *RG2* antigen(s) and inflammatory cytokine drivers of lupus pathogenesis.

*RG2* antigens cross-react with lupus anti-dsDNA antibodies {#s3-6}
-----------------------------------------------------------

To evaluate for relationships between anti-self and anti-*RG2* responses in patients with lupus, we assessed the capacity of native DNA and *RG2* extract to inhibit lupus serum IgG binding ([online supplementary figure 2A, B](#SP8){ref-type="supplementary-material"}). As expected, in side-by-side assays, soluble *RG2* extract was an efficient inhibitor of the binding of lupus serum IgG to immobilised treated *RG2* extract ([online supplementary figure 2C](#SP8){ref-type="supplementary-material"}). Yet, native DNA only marginally inhibited IgG binding to *RG2* extract ([online supplementary figure 2D](#SP8){ref-type="supplementary-material"}). In contrast, *RG2* extracts displayed marked dose-dependent inhibition of binding of lupus serum IgG to native DNA, whereas *RG1* extracts caused little or no inhibition of DNA binding ([online supplementary figures 1I, 2B](#SP3 SP8){ref-type="supplementary-material"}). Strikingly, *RG2* displayed high-level (\~90% maximal) inhibition of the binding to native mammalian DNA ([online supplementary figure 2A](#SP8){ref-type="supplementary-material"}) that was nearly as efficient in inhibitory activity as soluble native DNA itself ([online supplementary figure 2B](#SP8){ref-type="supplementary-material"}).
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To further confirm the relevance of *RG2* epitopes with antinuclear antibody responses, we assessed the effect on IgG antibody reactivity with *Crithidia luciliae*, a protozoan with a kinetoplast organelle used to detect antibodies specific for chromatin.[@R32] As expected, preincubation with native DNA inhibited this antibody interaction ([online supplementary figure 2E-J](#SP8){ref-type="supplementary-material"}), and *RG2* strain was also inhibitory ([online supplementary figure 2J](#SP8){ref-type="supplementary-material"}), while a different *RG* strain (ie, *RG1*) was not ([online supplementary table 5](#SP7){ref-type="supplementary-material"} and [online supplementary figure 1I](#SP8){ref-type="supplementary-material"}), suggesting that the relevant cross-reactive antigen(s) is strain-restricted (ie, associated with *RG2* but not *RG1*). Collectively, we found that many patients with lupus have anti-dsDNA antibody responses that are cross-reactive with antigens in *RG2*, which is relevant to the notion that anti-DNA antibodies with great cross-reactivity more often have nephritogenic potential.[@R10]

*RG2* contains lipoglycan(s) with antigenic properties recognised by patients with lupus {#s3-7}
----------------------------------------------------------------------------------------

To isolate the lipoconjugates produced by *RG2*, we applied a validated Hydrophobic Interaction Chromatography (HIC)-based separation strategy to isolate specific cell wall moieties such as lipoteichoic acids (LTAs), lipoglycans (LGs or lipoproteins[@R33] from the *RG2* strain ([online supplementary figure 1J](#SP3){ref-type="supplementary-material"}). For further analyses, we combined fractions 23--27 (pool 2) and 28--31 (pool 3) ([online supplementary figure 1J](#SP3){ref-type="supplementary-material"}) and applied ^1^H NMR ([figure 3A](#F3){ref-type="fig"}) as well as mass spectrometric (MS) analysis ([figure 3B](#F3){ref-type="fig"} and online [supplementary figures 1K, L](#SP3){ref-type="supplementary-material"}), We thereby detected significant amounts of LGs, but the absence of ^31^P NMR signals (data not shown) indicated the absence of LTA molecules. We therefore termed these pools LG2 and LG3, respectively. Taken together, these analyses documented that LG2 and LG3 from the *RG2* strain each represent a series of distinct LGs ([online supplementary figure 1K, L](#SP3){ref-type="supplementary-material"}).

![The LG3 pool contains two major series of lipoglycan molecules. (A) The ^1^H NMR spectrum of native LG3, recorded in D~2~O at 300 K, shows signals typical for lipoglycans, for example, for methyl groups of N-acetyl sugars, other carbohydrates and aliphatic chains of the lipid anchor. (B) The charge-deconvoluted MS spectrum of negative ion mode analysis of native LG3. (C) The charge-deconvoluted MS spectrum of negative ion mode analysis of de-*O*-acylated LG3. (Alternate version of this spectrum with additional assigned peaks is shown in [online supplementary figure 1L](#SP3){ref-type="supplementary-material"}.) (C) The charge-deconvoluted MS spectrum of negative ion mode analysis of de-*O*-acylated LG3. LG3 contains two major series of lipoglycans (termed series A \[red\] and B \[dark blue\]), starting from molecules with molecular weights of 2499.091/2513.107/2527.122 Da (series A) and 3380.395/3394.410/3408.426 Da (series B), respectively. These molecules are present in a series of further hexose-substituted (△m =+162.05 Da) molecular species. All peaks are present with variations in fatty acid composition (△m=14.02 Da is equivalent to CH~2~) (B). The complexity of the mass spectrum of de-*O*-acyl LG3 (C) is significantly decreased because of the removal of fatty acids. The overall signal pattern of the two series of lipoglycan species is well preserved. For series B, subspecies with a further alanine-substitution are apparent (light blue). Sodium adducts are represented as △m=21.98 Da, labelled in *italic* style. Abundances were normalised to the respective base peak of the depicted spectral region.](annrheumdis-2018-214856f03){#F3}

Further structural analyses were performed after hydrazine treatment that cleaves off all ester-bound residues, such as fatty acids.[@R34] Compared with the MS spectrum of native LG3 ([figure 3B](#F3){ref-type="fig"} and online [supplementary Figure 1L](#SP3){ref-type="supplementary-material"}), the de-*O*-acyl LG3 displayed significantly decreased complexity ([figure 3C](#F3){ref-type="fig"}); in native LG3, the signals at 3380.395 Da, 3394.410 Da and 3408.426 Da (start of series B^native^ \[[figure 3B](#F3){ref-type="fig"}\]) shifted to the signal of 2931.966 Da in the spectrum of de-*O*-acyl LG3 (start of series B^de-*O*-acyl^ \[[figure 3C](#F3){ref-type="fig"}\]), due to the removal of two fatty acids with combined chain length from C30:0 to C32:0. These changes reflected mass differences of 448.43 Da, 462.44 Da or 476.46 Da, respectively. For this series, molecules with varying number of hexoses were also detectable, as the signal pattern displays mass differences of 162.05 Da. A similar pattern was observed in the lower molecular range between 2000 and 2800 Da ([figure 3C](#F3){ref-type="fig"}) for series A^de-*O*-acyl^, for example, signals at 2050.663 Da, 2212.716 Da, 2374.768 Da and 2536.820 Da, representing the corresponding de-*O*-acylated molecules present in series A^native^. Interestingly, LG2 mono-acyl variants of LGs of series A and B were also detected ([online supplementary figure 1K](#SP3){ref-type="supplementary-material"}), and LG2 had a third series (C^native^) of LG molecules that was also observed. Hence, although each of the three series most likely have differing core units, all LG variants display 'hexose-capping'. The complete structural characterisation of these LGs from *RG2* is beyond the scope of the current report. An analogous extraction of cell wall moieties from *RG1* did not result in any yields of similar LGs, which suggests that *RG* strains differ in their capacity to produce cell wall LGs.

For investigations of the potential immune epitope features of the *RG2* strain, we performed immunoblots with lupus IgG that detected high levels of oligomeric bands in the LG3 pool in the range of \~20--30 kDa protein markers, which resembled the reactivity pattern of protease-resistant antigens in the *RG2* extract that were absent in other *RG* strains ([figure 4A--D](#F4){ref-type="fig"}). In fact, preincubation of a lupus serum with LG3 at 2 µg/mL inhibited all immunoblot reactivity with the oligomeric antigenic bands in the LG2 and LG3 pools and with the nuclease-treated *RG2* extract, but did not affect the IgG reactivity with the protease-sensitive bands ([figure 4E, F](#F4){ref-type="fig"}). As predicted, lupus IgG immunoreactivity with these oligomeric bands was destroyed by periodate treatment ([figure 4G](#F4){ref-type="fig"}), further supporting the notion that these immunodominant epitopes are on glyco-conjugate molecules. Side-by-side bead-based assays confirmed that the cell wall LG3 pool expresses the strain-restricted immunodominant epitopes in *RG2* commonly recognised by lupus sera ([figure 4H](#F4){ref-type="fig"}).

![Lipoglycans from *RG2* represent immunodominant antigens for patients with SLE. Immunoblots of purified LG2 and LG3 pools, and *RG2* and *RG1* extracts, were performed with sera from (A) SLE-07, (B) SLE-127, (C) SLE-080 that react with the same protease-resistant bands in LG2, LG3 and *RG2* (red box), whereas (D) a healthy control reacts with distinct immunodominant antigens also recognised by patients with active SLE that are generally lower MW (blue box). (E) Immune recognition by serum antibodies in SLE-134 with oligomeric bands in LG2 and LG3, and *in RG2*, (F) are entirely inhibited by preincubation with LG2 at 2 µg/mL. (G) Periodate treatment before blotting destroys antigens in LG2 and LG3. Loading per lane is indicated above at µg/lane. Immunoblots were performed with serum at 1:200, with detection of IgG reactivity. (H) Serum levels of antibodies to LG3 pool and *RG2* extract were highly correlated. Levels were determined by bead-based assay side-by-side in sera from 40 patients with SLE with diverse disease activity scores. SLE, systemic lupus erythematosus.](annrheumdis-2018-214856f04){#F4}

Furthermore, *in vitro* assays using a reporter cell line transfected with the human TLR2 demonstrated dose-dependent stimulation for the *RG2* extract, and for the purified LG3, which was greater than for the LG2 sample, while the *RG1* bacterial extract was devoid of detectable activity under these conditions ([online supplementary figure 1M](#SP3){ref-type="supplementary-material"}). To confirm the responsible mechanism, when studies were repeated in the presence of anti-TLR2 antibodies there was inhibition of NF-κB activation ([online supplementary figure 1M](#SP3){ref-type="supplementary-material"}). Hence, the LG pools, isolated from the *RG2* strain, contain both strain-restricted carbohydrate-associated antigen(s) recognised by serum IgG in patients with SLE, and component(s) with immunostimulatory properties ([online supplementary figure 1M](#SP3){ref-type="supplementary-material"}), which might be lipoproteins that commonly copurify with LTA and/or LGs recovered using this HIC isolation protocol.[@R33]

Independent cohorts confirm the association of anti-*RG2* responses with LN {#s3-8}
---------------------------------------------------------------------------

In the NYU discovery cohort, patients with active nephritis at the time of blood sampling (based on activity criteria[@R19] had significantly raised levels of IgG anti-*RG2* strain-restricted antibodies ([figure 5A](#F5){ref-type="fig"}). To confirm this association, we studied a second independent cohort of 27 patients ([online supplementary table 1](#SP2){ref-type="supplementary-material"}) (Temple University) in which 11/27 had elevated IgG anti-*RG2* antibody reactivity, and of the 12 with active LN (based on level of proteinuria and/or concurrent biopsy data), 9 (75%) displayed high anti-*RG2* antibody levels ([figure 5B](#F5){ref-type="fig"}). In a third cohort of 17 patients with biopsy-documented active LN ([online supplementary table 1](#SP2){ref-type="supplementary-material"}) (The Ohio State University), 10 (59%) showed elevations of serum IgG anti-*RG2* responses, but by contrast such responses were absent in patients with primary membranous glomerulonephritis and ANCA-associated vasculitis (Welch test, p=0.0025) ([figure 5C](#F5){ref-type="fig"}). Furthermore, for a number of the patients in the NYU and Temple cohorts the LN diagnosis was confirmed by renal biopsy ([online supplementary table 1](#SP2){ref-type="supplementary-material"}). Inhibition studies of pooled sera from each of these three independent geographically separated cohorts confirmed that lupus-associated autoimmune IgG anti-native DNA responses were cross-reactive with epitope(s) in the *RG2* strain ([online supplementary figure 1N](#SP3){ref-type="supplementary-material"}). Taken together, in three independent cohorts high IgG anti-*RG2* antibody reactivity with cross-reactivity with anti-native DNA autoantibodies ([online supplementary figure 1N](#SP3){ref-type="supplementary-material"}) was commonly found in patients with LN from proliferative Class III and Class IV histopathology by ISN/RPS criteria[@R35] ([online supplementary table 1](#SP2){ref-type="supplementary-material"}).

![Active lupus nephritis is associated with elevated IgG anti-*RG2* antibodies. (A) Results from individuals in NYU cohort are shown, with comparisons to unaffected controls. (B) Results from individuals in the Temple University cohort with 16 patients with lupus without evidence of renal (ie, non-renal) are compared with 12 with active LN. (C) Results from 17 patients with biopsy-proven active LN from Ohio State University are compared with 6 patients with biopsy-proven idiopathic primary mesnagial glomerulonephritis (MGN) and 20 with IgA nephropathy (IgAN). The cut-off MFI value of 1900 for IgG anti-*RG2* (dotted line) was determined by mean for 57 + 2 SD from unaffected 23 healthy controls with gut microbiome data, 15 other healthy individuals, 13 with psoriatic arthritis, and 12 with osteoarthritis). Renal disease was determined by clinical criteria and/or biopsy. Anti-*RG*2 values were determined by bead-based assay, with significance assigned by Mann-Whitney test.](annrheumdis-2018-214856f05){#F5}

SLE is a condition that overwhelmingly affects women, and due to concerns that gut microbiome can vary based on sex alone,[@R36] our discovery cohort was restricted to female patients. Yet our confirmatory cohorts included several male patients, including individuals with active LN, who also commonly had elevated levels of serum IgG anti-*RG2* antibodies ([Figure 5](#F5){ref-type="fig"}, [supplementary table 1](#SP2){ref-type="supplementary-material"} and data not shown). Furthermore, raised serum IgG antibody responses to *R*G2 were found in patients with active LN of diverse race/ethnicity: African-American, Asian, Caucasian, as well as Hispanic-White and Hispanic-Black ([online supplementary table 1](#SP2){ref-type="supplementary-material"}), which is consistent with the commonness of these immune responses in the three lupus cohorts examined.

Discussion {#s4}
==========

Our surveys of a cross-sectional discovery cohort documented that the severity of specific patterns of dysbiosis generally correlated with clinical disease activity. The gut microbiome of patients with higher SLEDAI scores had greater restrictions in taxonomic diversity. Indeed, our analyses provide the first evidence that lupus is associated with intestinal outgrowths of *RG*, an obligate anaerobic species, in the Blautia genus within the *Lachnospiraceae* family of the class *Clostridia.* [@R23] *RG,* which is a common (but generally low-level abundance) commensal in the faecal communities of healthy controls,[@R37] was documented to be overrepresented, with \>5-fold outgrowths in patients with lupus, with the greatest expansion in those with high disease activity and especially LN. Patients with lupus in these three geographically dispersed cohorts commonly displayed *RG* strain-restricted host immune responses that were cross-reactive with anti-DNA immune responses.

Patients with lupus also displayed higher levels of gut secretory IgA, a numerical trend towards higher abundance of faecal sIgA-coated *RG* bacteria and other abnormalities associated with gut barrier dysfunction. Importantly, there was a significant direct relationship with lupus disease activity and with LN, and the highest levels of serum IgG anti-*RG* antibody responses primarily directed against a *RG* strain-restricted cell wall-associated LG-containing antigen. Whereas these *RG* antigens may leak out of the intestine to induce IgG antibody responses, conversely IgG cannot enter the gut lumen and reduce the representation of taxa such as *RG*. Notably, *RG2* LG-containing pools included moieties that were potent *in vitro* NF-κB immune activators via TLR2 ([online supplementary figure 1M](#SP3){ref-type="supplementary-material"}) that has previously been implicated in lupus pathogenesis.[@R38] We speculate that the cross-reactivity of lupus autoreactive B cells to leaked stimulatory *RG* bacterial components, including TLR ligands(s), may contribute to the initiation and/or flares of lupus disease and especially LN that is a major source of early mortality and morbidity.[@R39]

In the human gut, the *Lachnospiraceae* family members fill a special niche, and degrade complex polysaccharides[@R40] including those of the intestinal mucus layer, which may lead to a leaky gut.[@R41] Yet *RG* strains vary greatly in their genomic composition, metabolic features and competitiveness. Indeed some isolates produce Lantibiotic polypeptides that suppress competing anaerobic species,[@R42] and experimental colonisation can cause shifts in T cell balance toward IL-17 production.[@R43]

RG outgrowths have recently been reported in patients with ankylosing spondylitis, and abundance was reported to correlate with greater disease activity.[@R45] In addition, patients with IBD have also been reported with RG blooms that comprised up to 69% of intestinal communities, and genomic analysis showed that these isolates were generally from a separate clade of *RG* than those in healthy individuals.[@R46] In the IBD microbiome, strain-specific genes involved in oxidative stress responses have recently been postulated to confer an advantage for *RG* strains[@R46] which could potentially be relevant to lupus pathogenesis as well.

The design of our observational studies has inherent limitations, as we do not currently know if *RG* expansions are truly causative or if lupus disease activity instead fosters preferential outgrowth of the candidate pathobiont. There is also a potential confounding effect of medications, as most patients were receiving treatment at the time of biosampling, and an enlarging list of medications is postulated to affect the balance of taxa within the gut microbiome community.[@R47] However, we discount this potential effect as several of the recruited patients were in-flare while off medication and the same *RG* outgrowths and immune responses were nonetheless found ([online supplementary table 1](#SP2){ref-type="supplementary-material"} and data not shown). The properties of the LGs in *RG2*, as well as other strains, will also require further investigation. In addition, Gram-positive opportunistic pathogens may have lipoproteins that are activators of innate immunity,[@R49] and such lipoproteins can be copurified along with other lipoconjugates using the HIC-based methodology. Hence, future studies will also need to directly assess the specific immunostimulatory properties of the LGs themselves.

Intestinal communities are complex, and emerging data suggest many pathways may be intertwined with lupus pathogenesis. Expansions of the commensal pathobiont species, Segmented Filamentous Bacteria, in susceptible mouse strains can contribute to antinuclear autoantibody production.[@R50] Furthermore, it has recently been reported that translocation and release of *Enterococcus gallinarum* from the small intestine may trigger the Aryl hydrocarbon receptor, resulting in autoantibody production and a type I interferon associated transcript signature in peripheral mononuclear cells.[@R51] Indeed, we speculate that multiple pathobionts, singly or in combination, may contribute to lupus pathogenesis, and hence our finding of concurrent *RG* outgrowths merit further examination in longitudinal studies, including inception cohorts as well as more in-depth mechanistic studies.

Conclusion {#s5}
==========

Mounting evidence suggests that overt lupus disease is often preceded by years of a preclinical phase with prominent circulating autoantibody responses.[@R52] Lupus disease has also been reported to be intertwined with greater inherent instability and lack of balance within the intestinal community[@R53] which could underlie the restricted taxa diversity and disease-associated *RG* outgrowths that we found. Indeed, the abundance of *RG* outgrowths correlated with lupus disease activity, with the greatest expansions in those with active renal disease, and these immune responses were primarily directed against a strain-restricted cell wall lipoglycan. Notably, individual lupus communities also displayed concordant significant expansions of *Veillonella* species, along with reciprocal contractions of *Bacteroides uniformis*. Furthermore, our findings also contribute to evidence of a widening range of inflammatory and autoimmune conditions associated with a 'leaky gut',[@R54] which may in part be responsible for the lupus-associated *RG* strain LG-directed antibody responses. We speculate that leakage of *RG* bacterial components contributes to nephritogenic autoantibody responses. To pursue these questions, it will be important to characterise the diversity and genetic features of *RG* strains and to understand when these strains colonise and expand in patients with lupus. In part, these investigations may lead to development of a biomarker assay that aids both earlier diagnosis and better prognostic determinations.
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